<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556332</url>
  </required_header>
  <id_info>
    <org_study_id>17-493</org_study_id>
    <nct_id>NCT03556332</nct_id>
  </id_info>
  <brief_title>A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation</brief_title>
  <official_title>Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test any good and bad effects of giving a combination of&#xD;
      study drugs before and after autologous stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, Simon two-stage phase II trial of combination therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with complete remission (CR) rate</measure>
    <time_frame>3 years</time_frame>
    <description>Traditional Response Criteria from International Myeloma Working Group Criteria for Multiple Myeloma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16</description>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days</description>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23</description>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)&#xD;
Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.&#xD;
Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.&#xD;
Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle.</description>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic cell transplantation</intervention_name>
    <description>High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine &gt;2mg/dL, they will receive 140 mg/m2.</description>
    <arm_group_label>Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab &amp; HCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be capable, willing, and able to provide written, informed consent.&#xD;
&#xD;
          -  Age ≥ 18-years-old and &lt;= 75-years-old.&#xD;
&#xD;
          -  Histologic confirmation of multiple myeloma by the enrolling institution&#xD;
&#xD;
          -  Symptomatic myeloma that has progressed/relapsed after 1 to 3 prior lines of therapy&#xD;
&#xD;
          -  Patients who have received &lt;=1 cycle of therapy after most recent progression/relapse&#xD;
             are eligible to enroll on study&#xD;
&#xD;
               -  Treatment of hypercalcemia or spinal cord compression or aggressively progressing&#xD;
                  myeloma with current or prior corticosteroids is permitted&#xD;
&#xD;
               -  Bisphosphonates are permitted&#xD;
&#xD;
               -  Concurrent or prior treatment with corticosteroids for indications other than&#xD;
                  multiple myeloma is permitted&#xD;
&#xD;
               -  Prior treatment with radiotherapy is permitted&#xD;
&#xD;
               -  Patients with measurable disease who received up to one cycle of any therapy&#xD;
                  within 60 days with a washout period of 4 weeks from last dose (on a trial or&#xD;
                  outside a trial) are eligible&#xD;
&#xD;
               -  Maintenance single agent imid (ie. lenalidomide or pomalidomide) or monoclonal&#xD;
                  antibody (ie. daratumumab) do not require the 4-week washout period&#xD;
&#xD;
          -  More than 2 x 10^6 autologous CD34+ cells/kg cryopreserved. The graft may not be CD34+&#xD;
             selected or otherwise manipulated to remove tumor or other cells. The graft can be&#xD;
             collected at the transplanting institution or by a referring center.&#xD;
&#xD;
          -  Planning to receive autologous HCT per institutional standards as part of standard of&#xD;
             care. Eligibility for autologous HCT should be based on institutional guidelines.&#xD;
&#xD;
          -  However, at minimum all patients must meet the following criteria:&#xD;
&#xD;
               -  KPS greater than 70&#xD;
&#xD;
               -  Cardiac left ventricular ejection fraction of greater than 40%&#xD;
&#xD;
               -  Calculated creatinine clearance of greater than 40 cc/min&#xD;
&#xD;
               -  AST and ALT of less than 2 x upper limit of normal&#xD;
&#xD;
               -  Direct bilirubin of less than 2 x upper limit of normal&#xD;
&#xD;
               -  Total bilirubin of less than 2 x upper limit of normal. If Total bilirubin is&#xD;
                  abnormal. Direct bilirubin of less than 2 x upper limit of normal&#xD;
&#xD;
          -  Measurable disease as defined by any of the following International Myeloma Working&#xD;
             Group Criteria&#xD;
&#xD;
               -  Monoclonal serum peak of greater than 0.5 gms per deciliter&#xD;
&#xD;
               -  Measurable urine peak as defined by urine protein electrophoresis of greater than&#xD;
                  100 mg per 24 hours&#xD;
&#xD;
               -  Serum FLC assay: involved FLC level ≥10 mg/dL provided serum FLC ratio is&#xD;
                  abnormal&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to enrollment (subjects may be&#xD;
             receiving red blood cell [RBC] transfusions in accordance with institutional&#xD;
             guidelines)&#xD;
&#xD;
          -  Platelet count ≥ 50 × 109/L (≥ 30 × 109/L if myeloma involvement in the bone marrow is&#xD;
             &gt; 50%) within 14 days prior to initial treatment (subjects may be receiving platelet&#xD;
             transfusions in accordance with institutional guidelines) .&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) † must agree to ongoing pregnancy testing and&#xD;
             to practice contraception as described in section 9.3 and required by the Revlimid&#xD;
             REMS program.&#xD;
&#xD;
             † A woman of childbearing potential is a sexually mature female who has not undergone&#xD;
             a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for&#xD;
             at least 24 consecutive months (i.e. has had menses at any time in the preceding 24&#xD;
             consecutive months).&#xD;
&#xD;
          -  Male subjects must agree to practice contraception&#xD;
&#xD;
          -  All study participants must be registered into the mandatory Revlimid REMS program and&#xD;
             be willing and able to comply with the requirements of the REMS program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plasma cell leukemia (&gt;20% circulating plasma cells) during screening studies&#xD;
&#xD;
          -  POEMS syndrome&#xD;
&#xD;
          -  Pregnant or lactating females. Because there is a potential risk for adverse events&#xD;
             nursing infants secondary to treatment of the mother with carfilzomib in combination&#xD;
             with lenalidomide. These potential risks may also apply to other agents used in this&#xD;
             study.&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
               -  Patients with HBV core antibody positive, but HBV PCR negative are eligible if&#xD;
                  they are on medication for suppression of HBV reactivation&#xD;
&#xD;
               -  Patients with HCV antibody positive, but PCR negative are eligible.&#xD;
&#xD;
          -  Serologically positive HIV (testing required during screening)&#xD;
&#xD;
          -  Significant cardiovascular disease with NYHA Class III or IV symptoms, EF&lt;40% or&#xD;
             hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction&#xD;
             within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as&#xD;
             determined by history and physical examination. Echocardiogram will be performed&#xD;
             during screening evaluation.&#xD;
&#xD;
          -  Moderate or severe pulmonary hypertension defined as PASP &gt;50 mm Hg&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1&#xD;
             second (FEV1) &lt; 50% of predicted normal. Note that FEV1 testing is required for&#xD;
             participants suspected of having COPD and participants must be excluded if FEV1 is &lt;&#xD;
             50% of predicted normal.&#xD;
&#xD;
          -  Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma&#xD;
             of any classification. Note that participants who currently have controlled&#xD;
             intermittent asthma or controlled mild persistent asthma are allowed to participate.&#xD;
&#xD;
          -  Refractory GI disease that would prevent absorption of oral agents&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to active infection or&#xD;
             psychiatric illness/social situations that would compromise compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Significant neuropathy ≥Grade 3 or Grade 2 neuropathy with pain at baseline&#xD;
&#xD;
          -  Contraindication to any concomitant medication, including antivirals or&#xD;
             anticoagulation.&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to first dose&#xD;
&#xD;
          -  Prior Allogeneic HCT (prior autologous transplant is allowed regardless of response)&#xD;
&#xD;
          -  History of CNS involvement by myeloma&#xD;
&#xD;
          -  Disease progression as defined by IMW Criteria1 on the combination of carfilzomib,&#xD;
             lenalidomide and dexamethasone (Patients with progression on lenalidomide maintenance&#xD;
             after completion of carfilzomib, lenalidomide and dexamethasone combination therapy&#xD;
             will be eligible).&#xD;
&#xD;
          -  Disease progression on daratumumab&#xD;
&#xD;
          -  Prior dose limiting toxicity from carfilzomib or lenalidomide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunjan Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunjan Shah, MD</last_name>
    <phone>212-639-8356</phone>
    <email>shahg@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Giralt, MD</last_name>
    <phone>212-639-3859</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Bal, MD</last_name>
      <phone>205-801-9034</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noa Biran, MD</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthee-lu Bayer, MD</last_name>
      <phone>516-734-8973</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD, MS</last_name>
      <phone>212-639-8356</phone>
    </contact>
    <investigator>
      <last_name>Gunjan Shah, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunjan Shah, MD</last_name>
      <phone>212-639-8356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Chhabra, MD, MS</last_name>
      <phone>414-805-0505</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>salvage autologous hematopoietic cell transplantation</keyword>
  <keyword>17-493</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

